Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway.

C Li, Z Chen, H Yang, F Luo, L. Chen, H Cai, Y. Li, G You, D Long, S Li, Qiuping Zhang, L Rao

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)
196 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway.'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science